Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Subscribe To Our Newsletter & Stay Updated
